Pharmadrug Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0052
- Today's High:
- $0.0055
- Open Price:
- $0.0052
- 52W Low:
- $0.0041
- 52W High:
- $0.0248
- Prev. Close:
- $0.0052
- Volume:
- 52920
Company Statistics
- Market Cap.:
- $1.86 million
- Book Value:
- 0.023
- Revenue TTM:
- $493051
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $182037
- Profit Margin:
- 0%
- Return on Assets TTM:
- -6.2%
- Return on Equity TTM:
- -12.45%
Company Profile
Pharmadrug Inc had its IPO on under the ticker symbol LMLLF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Pharmadrug Inc has a staff strength of 0 employees.
Stock update
Shares of Pharmadrug Inc opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.01, and closed at $0.01.
This is a 0% increase from the previous day's closing price.
A total volume of 52,920 shares were traded at the close of the day’s session.
In the last one week, shares of Pharmadrug Inc have slipped by -7.14%.
Pharmadrug Inc's Key Ratios
Pharmadrug Inc has a market cap of $1.86 million, indicating a price to book ratio of 0.5455 and a price to sales ratio of 7.8596.
In the last 12-months Pharmadrug Inc’s revenue was $493051 with a gross profit of $182037 and an EBITDA of $-399871. The EBITDA ratio measures Pharmadrug Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pharmadrug Inc’s operating margin was 0% while its return on assets stood at -6.2% with a return of equity of -12.45%.
In Q2, Pharmadrug Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 38%.
Pharmadrug Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pharmadrug Inc’s profitability.
Pharmadrug Inc stock is trading at a EV to sales ratio of 8.9772 and a EV to EBITDA ratio of -0.5818. Its price to sales ratio in the trailing 12-months stood at 7.8596.
Pharmadrug Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.88 million
- Total Liabilities
- $2.56 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Pharmadrug Inc ended 2024 with $11.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.88 million while shareholder equity stood at $8.24 million.
Pharmadrug Inc ended 2024 with $0 in deferred long-term liabilities, $2.56 million in other current liabilities, in common stock, $-25160667.00 in retained earnings and $6.24 million in goodwill. Its cash balance stood at $9923.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Pharmadrug Inc’s total current assets stands at $1.11 million while long-term investments were $0 and short-term investments were $108628.00. Its net receivables were $0 compared to accounts payable of $599773.00 and inventory worth $0.
In 2024, Pharmadrug Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Pharmadrug Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $0.0248
- 52-Week Low
- $0.0041
- Analyst Target Price
- $
Pharmadrug Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $0.0248 and a 52-week low of $0.0248. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.01 and 200-day moving average was $0.01 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 178.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Pharmadrug Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to vertically integrated elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine’s (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. Further, the company also holds interest in Sairiyo Therapeutics Inc. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug Inc. is based in Toronto, Canada.